Christopher Antolini, MD
Rheumatology · Denver, CONPI 1750302592
Payments from drug & device makers
Across 931 payments — averaging $7416.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$4.5M
- Novartis$606K
- AbbVie$369K
- Janssen Research & Development, LLC$348K
- Eli Lilly$282K
- UCB SA$192K
- plus $565K from 31 others
Across 2 payments — averaging $505.40 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$1K
What the payments were for
- Speaking & faculty fees$23,90070%
- Travel & lodging$2,8708%
- Food & beverage$7,31721%
- Education$210%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 85 | $4,542,985 |
| Novartis | 59 | $605,925 |
| AbbVie | 229 | $369,087 |
| Janssen Research & Development, LLC | 58 | $347,929 |
| Eli Lilly | 32 | $282,368 |
| UCB SA | 36 | $191,624 |
| Astrazeneca UK Limited | 11 | $137,564 |
| GSK | 85 | $125,910 |
| E.r. Squibb & Sons, L.L.C. | 27 | $86,813 |
| Sun Pharmaceutical Industries Inc. | 120 | $56,739 |
| Gilead | 13 | $41,966 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $40,880 |
| Sanofi US Services Inc. | 8 | $30,047 |
| Argenx US, Inc. | 20 | $14,998 |
| Biogen | 1 | $13,056 |
| Pfizer | 45 | $8,155 |
| Astrazeneca AB | 1 | $7,000 |
| Genentech USA, Inc. | 25 | $448 |
| Johnson & Johnson | 8 | $374 |
| AstraZeneca | 9 | $165 |
| UCB, Inc. | 6 | $127 |
| Lilly USA, LLC | 8 | $123 |
| Radius Health, Inc. | 6 | $105 |
| UCB GmbH | 1 | $103 |
| Regeneron Healthcare Solutions, Inc. | 5 | $79 |
| Aurinia Pharma U.S., Inc. | 3 | $76 |
| ANI Pharmaceuticals, Inc. | 4 | $75 |
| Mallinckrodt Hospital Products Inc. | 3 | $59 |
| Sobi, Inc | 2 | $47 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $42 |
| Ferring Pharmaceuticals Inc. | 2 | $36 |
| Sanofi | 2 | $32 |
| Regeneron | 1 | $24 |
| Organon | 1 | $20 |
| Boehringer Ingelheim | 1 | $18 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $17 |
| Fidia Pharma USA Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Prolia$23,952
- EVENITY$1,152
- Tremfya$250
- SIMPONI ARIA$250
- XELJANZ$116
How this compares
$6,905,034 in reported general payments places this provider in the 95th percentile of 108 rheumatology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TremfyaGuselkumab | 14 | $195,899 |
| RinvoqUpadacitinib | 20 | $166,665 |
| Taltz AutoinjectorIxekizumab | 15 | $104,588 |
| Enbrel SureclickEtanercept | 14 | $102,709 |
| Orencia ClickjectAbatacept | 17 | $96,604 |
| OtezlaApremilast | 18 | $85,303 |
| OrenciaAbatacept | 12 | $71,183 |
| Actemra ActpenTocilizumab | 12 | $55,263 |
| Hydroxychloroquine Sulfate | 192 | $8,038 |
| Mycophenolate Mofetil | 12 | $6,799 |
| MethotrexateMethotrexate Sodium | 164 | $4,644 |
| Febuxostat | 40 | $4,122 |
| Prednisone | 304 | $2,479 |
| Celecoxib | 79 | $2,269 |
| Tramadol Hcl | 164 | $1,536 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonTremfya | $374 | $195,89914 claims |
| AbbVieRinvoq | $369,087 | $166,66520 claims |
| AmgenOtezla | $4,542,985 | $85,30318 claims |
| E.r. Squibb & Sons, L.L.C.Orencia | $86,813 | $71,18312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 108 rheumatology providers in Colorado.
Other rheumatology in Denver
- Mary DemoruelleDenver$1.2M
- Aryeh FischerDenver$193K
- Adam BerlinbergDenver$94K
- Stuart KassanDenver$75K
- Mehrnaz Maleki FischbachDenver$72K
- Rennie McCabeDenver$58K
- Barbara GoldsteinDenver$47K
- Vance BrayDenver$42K
- Joel HirshDenver$33K
- Liudmila KastsianokDenver$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.